Table 4 Outcomes for patients with AKI stratified depending on whether they took anticoagulation or not
| Â | Â | Overall-AKI | Not anticoagulated-AKI | Anticoagulated-AKI | p-value | |
|---|---|---|---|---|---|---|
n | Â | 210 | 171 | 39 | Â | |
Died (%) | Â | 110 (52.4) | 91 (53.2) | 19 (48.7) | 0.741 | |
30-day mortality (%) | Â | 97 (46.2) | 80 (46.8) | 17 (43.6) | 0.855 | |
Readmit within 30 days (%) |  | 13 (6.2) | 10 (5.8) | 3 (7.7) | 0.95 | |
Time to AKI from admission, days |  | 0.00 (0.00–4.00) | 0 (0.00–4.00) | 1.00 (0.00–4.00) | 0.966 | |
Time to AKI from COVID diagnosis, days |  | −1.00 (1.00–2.00) | −1.00 (− 1.00–1.00) | 0 (−2.50–2.50) | 0.977 | |
Initial AKI stage | 1 | 123 (58.6) | 99 (57.9) | 24 (61.5) | 0.380 | |
2 | 37 (17.6) | 33 (19.3) | 4 (10.3) | Â | ||
3 | 50 (23.8) | 39 (22.8) | 11 (28.2) | Â | ||
Peak AKI stage | 1 | 75 (35.7) | 62 (36.3) | 13 (33.3) | 0.783 | |
2 | 43 (20.5) | 36 (21.1) | 7 (17.9) | Â | ||
3 | 92 (43.8) | 73 (42.7) | 19 (48.7) | Â | ||
Day zero Sodium | mmol/L | 138.00 (133.00–142.00) | 138.00 (133.00–142.00) | 138.00 (134.50–142.50) | 0.758 | |
Peak | Urea | mmol/L | 18.40 (12.80–27.30) | 18.25 (12.43–26.98) | 18.60 (14.10–29.05) | 0.591 |
Creatinine | μmol/L | 189.00 (136.00–305.00) | 187.00 (135.25–311.50) | 191.00 (143.50–260.50) | 0.831 | |
CRP | nmol/L | 208.00 (107.00–312.00) | 231.00 (110.25–317.75) | 169.00 (94.50–218.50) | 0.054 | |
Minimum | Haemoglobin | g/L | 96.00 (76.00–117.00) | 96.00 (74.25–116.75) | 97.00 (86.00–124.50) | 0.36 |
Lymphocytes | 109/L | 0.64 (0.41–0.89) | 0.64 (0.41–0.95) | 0.63 (0.47–0.86) | 0.941 | |
Went to critical care | Â | 73 (34.8) | 65 (38.0) | 8 (20.5) | 0.06 | |
Died in critical care (%) | Â | 38 (52.1) | 33 (50.8) | 5 (62.5) | 0.801 | |
Ventilation (%) | Â | 63 (86.3) | 59 (90.8) | 4 (50.0) | 0.009 | |